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a b s t r a c t
Vaccines to methamphetamine (meth) were designed by covalently attaching a meth hapten (METH)
to peptide constructs that contained a conformationally biased, response-selective molecular adjuvant,
YSFKPMPLaR (EP54). Rats immunized with EP54-containing meth vaccines generated serum antibody
titers to authentic meth, an immune outcome that altered meth self-administration. Immunization
increased meth self-administration suggesting pharmacokinetic antagonism. The ability of immune sera
to bind a METH-modified target protein dramatically decreased during and shortly after the meth self-
administration assay, suggesting effective sequestration of free meth. However, the binding ability of
immune sera to theMETH-modified target proteinwas recovered 34 days aftermeth-free clearance time.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
The illicit manufacture, distribution, and abuse of metham-
phetamine (meth) have risen dramatically in the past decade
imposing enormous public health, welfare, and law enforcement
burdens worldwide. Meth represents the fastest growing drug
threat in the United States [1] and is a major problem in the
American Midwest [1–3], a rural region that provides access to
agricultural ammonia, a key ingredient in its illicit synthesis, and a
remote setting that enables makeshift laboratories to operate in a
more clandestine manner. Of particular concern is the strong asso-
ciation between this increase in meth abuse and the transmission
of communicable diseases such as hepatitis A [4].
The scourge of meth abuse and its devastating effects on soci-
ety and family life underscore the need for an effective method of
inhibiting its addictive, pharmacologic effects. Presently, no direct
interventionmethod exists, themainstay of therapy being behavior
modification and treatment with antidepressants to help a patient
∗ Corresponding author. Tel.: +1 402 559 5353.
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through withdrawal. A bothersome issue with a highly addictive
drug like meth, however, is the high rate of relapse [5–8]. Thus, a
therapy is urgently needed that is capable of (1) effectively antag-
onizing the drug in circulation prior to its distribution to the brain
and (2) sustaining this antagonizing effect long enough tominimize
relapse. Such a therapy, when used as a complement to standard
treatments, would provide a powerful combination approach for
treating meth addiction.
An innovative therapeutic approach capable of providing these
latter two attributes is immunization with an appropriately
designed meth vaccine. Vaccination will induce the immune sys-
tem to generate meth-specific antibodies (Ab), which will bind
free meth in circulation with high affinity, thus decreasing/altering
meth distribution to the brain. Also, vaccination has the poten-
tial of sustaining this anti-meth immune response in the face of
repeated ingestions of meth and for a period of time beyond the
initial cessation of meth use, thus providing protection during that
crucial time framewhen the patient is highly susceptible to relapse.
Also, the antagonizing effects of such an immunologic approach
would occur outside the central nervous system (CNS) and would
not interfere with behavior modification or CNS-acting medica-
tions.
0264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2009.02.105
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Vaccines to cocaine [9,10], heroin [11], and nicotine [12–15] have
been used in the active immunization of rats and shown capable of
producing high sera titers of drug-specific Abs, which attenuated
the psychoactive and locomotor effects of subsequent drug chal-
lenges. These vaccines were generated via conventional designs
wherein multiple drug haptens were covalently conjugated to a
carrier protein, which was then admixed with an adjuvant for the
deliverable drug vaccine.
Byrnes-Blake et al. [16] showed appreciable serum titers of
anti-meth Abs in rats immunized with a similarly designed meth
vaccine. Importantly, they showed that neither Ab titer nor Ab
affinity were affected by the concomitant administration of meth
during the course of immunization, suggesting that meth use dur-
ing a patient’s immunization schedule (a likely scenario) will not
adversely affect the production of anti-meth Abs. Unfortunately,
this anti-meth Ab response was ineffective in attenuating loco-
motor activities in rats challenged with meth, suggesting that the
vaccine design and/or its administration schedule were not opti-
mized.
In this paper we describe the design of novel, peptide-based,
molecular adjuvant-containing vaccines to meth and their use in
producing short-term and long-term anti-meth outcomes in rats.
The vaccines used in this study were composed of three basic
components, the first being the molecular adjuvant, YSFKPMPLaR
(EP54), which is a conformationally biased, response-selective ago-
nist of complement component C5a65–74. EP54 retains C5a-like
immune stimulatory properties, but with significantly reduced
C5a-like inflammatory properties [17–20]. The role of the molecu-
lar adjuvant EP54 in these vaccines is to target covalently attached
Ags to and activate the Ag processing and presentation capacity of
C5a receptor-bearing antigen presenting cells [21–23], particularly
dendritic cells (DCs) [24].
The second vaccine component is a T-cell epitope from tetanus
toxin TT593–599 (YSYFPSV) [25], which was covalently attached to
the N-terminus of EP54. This epitope was used to engage CD4+
helper T-cells in order to provide the necessary T-cell help for the
Ab-producing B cells during epitope/hapten presentation by DCs
activated by EP54. The third component is a meth hapten (METH)
synthesized to allow the covalent attachment (via amide bond for-
mation) to either the N-termini of the TT epitope-EP54 peptide or
EP54 (monovalent vaccines) or also to the ε-amino group of an
extra Lys residue, which was added to the N-terminal end of the
TT epitope-EP54 peptide or EP54 (divalent vaccines).
In this paper we present the immunologic outcomes of rats vac-
cinated with these EP54-containing vaccines in terms of initial and
sustained meth-specific serum Ab titers and their ability to atten-
uate/alter meth self-administration. These results are discussed
against the backdrop of such an immunologic approach being used
as a routine method of treating meth abuse/addiction.
2. Materials and methods
2.1. Peptide synthesis
Peptides were synthesized by standard solid phase meth-
ods on an Aapptec Apex 396 synthesizer using the Fmoc
(9-fluorenylmethoxycarbonyl)methodof orthogonal synthesis on a
pre-loadedFmoc-ArgWang resin. Peptideswerepurifiedbyprepar-
ative and analytical HPLC and characterized by confirmation of
molecular mass with MALDI mass spectrometry (see below).
2.2. Hapten (METH) synthesis (Scheme 1)
The METH hapten shown in Scheme 1 was synthesized by a
modification of the basic scheme described by Byrnes-Blake et al.
[16]. Confirmation of the chemical modifications contained in our
homologues, aswell as synthetic yields, were consistentwith those
reported for the parent hapten [16].
2.2.1. (S)-N-methyl-N-(1-methyl-2-phenylethyl)acetamide (2)
S-(+)methamphetamine (1) (2.23 g, 14.9mmol) was dissolved
in 100ml dichloromethane (CH2Cl2) containing five equivalents
(10.4ml) of triethylamine (TEA). To this stirred solution was added
18mmol (1.42g) of acetyl chloride dropwise over 10min. This solu-
tion was stirred overnight at room temperature and the solvent
removed in vacuo. The residue was dissolved in CH2Cl2 (75ml),
Scheme 1.
M.J. Duryee et al. / Vaccine 27 (2009) 2981–2988 2983
washed two times each with 1N HCl, saturated brine, water, and
dried over Mg2SO4. The CH2Cl2 was removed in vacuo to yield S-
(+)-N-acetylmethamphetamine (2) as a light brown oil. The NMR
spectra indicated a 1:1-mixture of rotamers. 1H NMR (500MHz,
CDCl3) ı 1.10 (d, J=6.8Hz, 1.5 H), 1.26 (d, J=6.4Hz, 1.5H), 1.75 (s,
1.5H), 1.98 (s, 1.5H), 2.64–2.82 (m, 2H), 2.78 (s, 1.5H), 2.85 (s, 1.5H),
3.96–4.09 (m, 0.5H), 4.99–5.09 (m, 0.5H), 7.09–7.35 (m, 5H). MF,
C12H17NO; MH+ =192.
2.2.2. (S)-4-[2-(acetylmethylamino)propyl]--oxobenzenebut-
anoic acid ethyl ester (3)
To a mixture of compound 2 (5.38 g, 28.13mmol) in CH2Cl2
(100ml) at 0 ◦C was added ethyl succinyl chloride (9.26g,
56.26mmol) followed by AlCl3 (17.87g, 134mmol) in three por-
tions. The reaction was stirred overnight at room temperature,
cooled to 0 ◦C, and quenched with 3M aqueous HCl (100ml). After
the mixture was diluted with CH2Cl2 (100ml), the organic layer
was separated, washed with 3M aqueous HCl (100ml) and water
(200ml), dried over MgSO4, and concentrated to give a crude
product (14.18g) that was used in the next step without further
purification. The NMR spectra indicated 3:2-mixture of rotamers.
1HNMR(500MHz, CDCl3) ı1.14 (d, J=6.4Hz, 1.8H), 1.27 (t, J=6.9Hz,
3H), 1.28 (d, J=6.4Hz, 1.2H), 1.81 (s, 1.2H), 2.02 (s, 1.8H), 2.61–2.92
(m, 4H), 2.80 (s, 1.8H), 2.87 (s, 1.2H), 3.29 (t, J=6.6Hz, 2H), 4.01–4.11
(m, 0.4H), 4.16 (q, J=6.9Hz, 2H), 5.01–5.11 (m, 0.6H), 7.19–7.36 (m,
2H), 7.85–7.98 (m, 2H).
2.2.3. (S)-4-[2-(acetylmethylamino)propyl]benzenebutanoic acid
ethyl ester (4)
A mixture of compound 3 (14.18g, crude product from the last
step) and 10wt% Pd/C (1.40g) in acetic acid (50ml) was stirred at
room temperature under H2 atmosphere for 48h. After the mix-
ture was filtered and rinsed with CH2Cl2 (200ml), the filtrate was
diluted with CH2Cl2 (100ml), washed with water (200ml) and
saturated aqueous NaHCO3 (100ml), dried over MgSO4, and con-
centrated to give compound 4 as a brown oil (6.97 g, 81%; the
combined yield for the last two steps). The NMR spectra indi-
cated 1:1-mixture of rotamers. 1H NMR (500MHz, CDCl3) ı 1.09
(d, J=6.8Hz, 1.5H), 1.24 (d, J=6.8Hz, 1.5H), 1.25 (t, J=6.8Hz, 3H),
1.75 (s, 1.5H), 1.88–1.96 (m, 2H), 1.99 (s, 1.5H), 2.30 (t, J=7.6Hz, 2H),
2.56–2.81 (m, 4H), 2.78 (s, 1.5H), 2.84 (s, 1.5H), 3.95–4.06 (m, 0.5H),
4.09–4.19 (m, 2H), 4.95–5.06 (m, 0.5H), 6.98–7.15 (m, 4H).
2.2.4. (S)-4-[2-(methylamino)propyl]benzenebutanoic acid
hydrochloride (5) (METH).
A mixture of compound 4 (6.97 g, 22.8mmol) and 6M aqueous
HCl (120ml) was refluxed for 72h. After cooling to room temper-
ature, the mixture was concentrated in vacuo. The residue was
purified by crystallization from ether followed by crystallization
from acetonitrile to give the desired compound 5 as a colorless
solid (2.10 g, 34%) mp 130–132 ◦C. 1H NMR (500MHz, DMSO–d6)
ı 1.08 (d, J=6.3Hz, 3H), 1.71–1.82 (m, 2H), 2.19 (t, J=7.1Hz, 2H),
2.51–2.64 (m, 6H), 3.08–3.18 (m, 1H), 3.25–3.34 (m, 1H), 7.15 (s,
4H), 9.04 (brs, 2H), 12.05 (s, 1H); 13C NMR (125.7MHz, DMSO–d6) ı
15.15, 26.40, 29.71, 33.24, 34.15, 38.05, 55.44, 128.71, 129.40, 134.25,
140.20, 174.40.
2.3. Vaccine synthesis
Monovalent (METH-YSFKPMPLaR and METH-YSYFPSVYSFKPM-
PLaR) and divalent (METH-K(METH)YSFKPMPLaR and METH-
K(METH)YSYFPSVYSFKPMPLaR) vaccines were generated by cou-
pling METH (5) to the N-terminal and ε-amino moieties of
these peptides while attached to the solid phase resin [15]. The
corresponding free amino groups were generated by selective
deprotectionof Fmocgroups andamidebond formationwithMETH
wasachievedby reactionwith theHBTU (2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate)-activated ester
of METH. The course of this coupling reaction was monitored by
the loss of the free amine on the peptide with ninhydrin. The
peptide-based vaccines were cleaved from the resin and side-chain
protecting groups removed by stirring the resin for 1.5h at room
temperature in a cleavage cocktail made of TFA (92.5%), water (5%),
and triisopropylsilane (2.5%). To this solution was added an excess
(ca. 100ml) of cold ether to precipitate the peptide, which was
then collected by centrifugation. Peptides were purified by ana-
lytical and preparative reverse-phase HPLC on C18-bonded silica
columns with a running buffer of 0.1% TFA (Solvent A) and 60%
acetonitrile in 0.1% TFA (Solvent B) as the eluant. Peptides were
characterizedbyconfirmationofmolecularmassusingMALDImass
spectrometry.
2.4. Vaccination
Rats were randomly assigned to either the Vaccine or Control
group. The Vaccine group received two injections of 250g of
vaccinedissolvedat 1mg/ml in sterilewater. One injectionwas sub-
cutaneous (SC) and the other was intraperitoneal (IP). The Control
group received the same number and volume of vehicle injections.
This vaccination procedure was repeated once every 7 days for 5
weeks and serum was collected at weeks 1, 3, and 6. The final
vaccination occurred on the last day of Preliminary Training (see
below).
2.5. Determination of Abs to methamphetamine
Prior to immunization of meth administered rats a group was
tested to determine vaccine efficacy. Briefly, 4 rats were immu-
nized with vaccine as described above and bled via retro orbital
puncture. A direct ELISA was used to determine circulating anti-
body titers tometh. Serumwasdiluted2-foldandmultipledilutions
were averaged to determine concentration from the rat IgG stan-
dard curve. Using METH-modified BSA (bovine serum albumin),
ELISA plates (Immulon IV, Dynatech, Chantilly, VA) were coated
at 2g/well in the presence of bicarbonate buffer, pH 9.6 and
incubated at 37◦ overnight. Plates were washed, blocked using
2% casein for 30min and rat serum incubated on the plate for
1h at room temperature. The plates were then washed and
horse raddish peroxidase (HRP) rabbit anti-rat IgG (H&L) anti-
body added (Sigma Chemical, Co., St. Louis, MO), incubated for
30min, and developed using TMB substrate. Absorbance was
detected at 450nm using an MRX II Microplate Reader (Dynat-
ech, Chantilly, VA), data analyzed using Revelations Software from
Dynatech, and expressed in ng/ml using rat IgG as a standard
curve.
2.6. Competitive ELISA
In order to determine the specificity of the Abs raised against
meth, a competitive ELISA was used as previously described [15].
ELISA plates were coated with METH-modified BSA as described
above and incubated overnight. In a separate radioimmuno-assay
(RIA)plate, themeth inhibitor and serumwerediluted for overnight
incubationat 4 ◦C.Methwasdiluted2-folddown theplate at a start-
ing concentration of 2000pmol/well. Serum from immunized rats
was added to the plate at a concentration that would produce a 1.0
O.D. after 30min of incubation. Following an overnight incubation,
the plate was washed, blocked in 2% casein, and the RIA plate con-
tents transferred over. After 1h incubation at room temperature,
the plate was washed and an HRP rabbit anti-rat IgG (H&L) (from
above) was added for 30min. The plate absorbance was detected
as previously described above. Calculation of the competitive ELISA
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was determined using the following formula:
inhibition (%) = (OD max -BKG) − (ODsample-BKG)
(OD max -BKG)
× 100
2.7. T-cell proliferation assays
To determine proliferative responses of T-cells, PBS (control) or
METH-modified BSA were added to 96-well flat bottom plates at
a concentration of 50g/ml. T-cells from immunized and sham
immunized (vehicle control) rats were added at a concentration of
(1×105 cells/well) and incubated for 48h at 37 ◦C in 5% CO2, pulsed
with 1.0Ci/well of [3H] thymidine (GE Healthcare, Piscataway, NJ)
for 16h, and harvested on a 96-well harvester (Tomtec, Orange,
CO). Filter paper containing the incorporated thymidinewas placed
in scintillation fluid and counted on a 1450 Microbeta Scintilla-
tion Counter (Perkin Elmer Life Sciences, Waltham, MA). Data was
expressed as stimulation index (SI) using the following formula:
SI = (mean cpm/min of target − BKG)
(mean cpm/mlof control − BKG)
2.8. Self-administration apparatus
Eight standard self-administration chambers (Med-Associates,
Georgia, VT, USA) were used each housed in a PVC sound-
attenuating cubicle fitted with an exhaust fan and a house light.
Each chamber (30.5 cm×24.1 cm×21 cm; l×w×h) had side walls
made of aluminum; the ceiling and front and back walls were clear
polycarbonate. In the bottom center of one aluminum wall was a
recesseddipper receptacle (5.2 cm×5.2 cm×3.8 cm; l×w×d). The
dipper arm, when raised, allowed access to 0.1ml of 26% sucrose
solution (w/v). Retractable levers were located on either side of the
dipper receptacle. To operate the lever required 147nN of force.
Twowhite cue lights (28V, 100mA)were centered 7 cm above each
lever, 14.6 cm above themetal rod floor and 3.5 cm from the closest
polycarbonate wall. Each chamber contained a balancedmetal arm
with a spring leash attached to a swivel. Tygon® tubing AAQ04103
(VWR, West Chester, PA, USA) extended through the leash and was
connected to a 5ml syringe mounted on an infusion pump (Med
Associates, PMH-100VS) located outside of the PVC cubicle.
2.9. Meth self-administration methods
2.9.1. Subjects
Ten male Wistar rats weighing 150–175g upon arrival from
Charles River Laboratories, Inc. (Wilmington, MA, USA) were
housed individually in clear polycarbonate tubs lined with wood
shavings. Water was continuously available in the home cage and
access to chow was restricted during Preliminary Training and
Self-Administration. All sessions were conducted during the light
portion of a 12h light/dark cycle. Experimental protocols were
approved by the University of Nebraska-Lincoln and University of
Nebraska Medical Center Institutional Animal Care and Use Com-
mittee and followed the “Guide for the Care and Use of Laboratory
Animals” (National Research Council, 1996).
2.9.2. Drug
d-Methamphetamine hydrochloride (meth) was purchased
from Sigma (St. Louis, MO, USA), dissolved in 0.9% sterile saline
(w/v), and administered intravenously (IV) at a volume of 36l per
infusion.
2.10. Preliminary training
Rats were fed 20g of chow per day during this phase. Dipper
training consisted of a 50min automated session inwhich the prob-
ability of receiving 4 s access to sucrose in any 4 s interval was
0.1333 (ca. 3 deliveries per min). Two days of lever press autoshap-
ing following dipper training. On a given session only one of the
retractable levers (right or left) was inserted into the chamber for
15 s using a variable time 60 s schedule. If a lever press occurred
before 15 s, the lever was retracted and sucrose was immediately
available for 4 s. If no lever press occurred after 15 s, the lever was
retracted and 4 s access to sucrosewas provided. Order of lever pre-
sentation (left or right on day 1) was counterbalanced as much as
allowed by sample size. There were 60 presentations of the lever
per session; thus, session length varied somewhat between rats
depending upon when consistent lever pressing developed in the
session. After the last autoshaping session, rats were allowed free
access to rat chow until the end of the surgical recovery period.
2.11. Catheter surgery
Surgery was performed 24h after the last vaccination and pro-
ceeded as described in detail elsewhere [26,27]. Briefly, rats were
anesthetized with 1ml/kg ketamine hydrochloride (100mg/ml, IP)
followed by 0.6ml/kg xylazine hydrochloride (20mg/ml, IP) (Mid-
western Veterinary Supply, Des Moines, IA, USA). One end of a
silastic catheter (CamCaths© IVSA28, Ely, Cambridgeshire, UK) was
implanted into the left external jugular vein. The other end of the
catheterwent subcutaneous around the shoulder andwas attached
to ametal cannula embedded in a plastic bolt that exited below the
scapula permitting access to the catheter. To manage post-surgical
pain, buprenorphinehydrochloride (0.1mg/kg; Sigma)was injected
SC immediately following surgery. For that evening and the follow-
ing day buprenorphine (0.5mg/kg) was available in the drinking
water. The catheter was flushed twice a day with 0.2ml of ster-
ile heparinized saline (30U/ml; Midwest Veterinary Supply). The
first five post-surgical flushes also included 0.1ml of streptokinase
(ca. 8000U/ml; Sigma) dissolved in heparinized saline. Catheter
patency of the 10 rats was confirmed with a 0.05ml IV infusion
of xylazine (20mg/ml) at the end of the study. This concentration
produces motor ataxia within 5 s if the catheter is patent.
2.12. Self-administration
Five days after surgery (7 days after the last vaccination) rats
started the self-administration phase. Sessions were 60min and
the house light remained on throughout each session. Which lever
(right or left) functioned as the active (drug) lever was counter-
balanced as permitted by sample size. The initial schedule of
reinforcement was a fixed ratio (FR) 1. Thus, each active lever press
produced a 1 s infusion of 0.05mg/kg meth and simultaneous illu-
mination of the cue light above the active lever. Both levers were
retracted and remained retracted for 1min following completion
of the FR1. Inactive lever presses were recorded but had no pro-
grammed consequence. Rats remained on an FR1 for 5 days. This
schedule was increased to an FR3 (5 days), followed by an FR5 (5
days), an FR10 (3 days), and finally a progressive ratio (1 day). Incre-
ments in theprogressive ratio (PR) schedulewithin sessionused the
formula 5×EXP (0.2× infusion number)–5 [28,29]. Similar to those
studies, we replaced the first six values (1, 2, 4, 6, 9, and 12) with 3,
6, and 10, and then continuedwith the progression provided by the
equation. The resulting sequence of required responses per infu-
sion was: 3, 6, 10, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 179, etc.
[Note: For the blood sample section the first blood collection was
approximately 24h after the PR schedule. The second sample was
taken 34 days later].
2.13. Dependent measures and data analysis
For each FR schedule, the number of methamphetamine infu-
sions was analyzed with a 2-way mixed analysis of variance
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Table 1
EP54 containing vaccines to methamphetamine.
Vaccine 1 METH-YSFKPMPLaR
Vaccine 2 METH-YSYFPSVYSFKPMPLaR
Vaccine 3
Vaccine 4
(ANOVA) with Group (Vaccine or Control) as the between-subjects
factor and Session as the within-subjects factor. To determine
when discrimination between the active and inactive lever was
acquired, the ratio of active to total lever presses was calculated
and then compared to a hypotheticalmean of 0.5. Acquisition of the
discrimination was declared when two consecutive session were
significantly above 0.5 (i.e., more than half the total responding
on the active lever). For the PR schedule, the last PR completed
(i.e., breakpoint) for each group was compared with an unpaired t-
test. Statistical significance for all analyses was set at P<0.05 with
a two-tailed rejection region.
3. Results
Four molecular adjuvant (EP54)-containing vaccines were used
in this study and are shown in Table 1. They consisted of two
monovalent vaccines (Vaccines 1 and 2) and two divalent vaccines
(Vaccines 3 and 4). Fig. 1 shows increased serum Ab reactivity at
week 6 to the METH hapten for Vaccine 2 (1716ng/ml±211) and
Vaccine 4 (858ng/ml±91) P≤0.001 compared to serum from rats
sham immunized with vehicle only (40ng/ml±15). Relative to the
other EP54-containing vaccines, Vaccine 2 appeared to generate the
highest serum Ab titers to METH (P≤0.001) and, therefore, was
chosen for use in subsequent experiments.
The specificity of these anti-METH Abs generated by Vaccine 2
to methamphetamine was determined using a binding inhibition
assay to the METH hapten in the presence of authentic metham-
phetamine. Fig. 2 indicates an 80% inhibition of the METH-positive
rat serum in the presence of free methamphetamine, demonstrat-
ing Ab specificity to the drug.
Fig. 1. Ab activity to methamphetamine in male Wistar rats immunized with:
vehicle control (PBS); METH-YSFKPMPLaR (Vaccine 1); METH-YSYFPSVYSFKPMPLaR
(Vaccine 2); METH-K(METH)YSFKPMPLaR (Vaccine 3); and METH-K(METH)YSYFP-
SVYSFKPMPLaR (Vaccine 4) at weeks 1, 3 and 6. Serum from rats was screened using
METH-modified BSA as the antigen and extrapolated using rat IgG as a standard
curve. Each bar represents themean± S.E. of 4 rats. *P≤0.001, significantly different
from the vehicle control. #P≤0.001 significantly different form all other vaccines.
Fig. 2. An example of Ab specificity to meth from rats vaccinated with Vaccine 2.
Sera were incubated in the presence of authentic meth as an inhibitor and then
allowed to bind the METH-modified BSA antigen. Data are expressed as % inhibition
of immune sera. Data are representative of 4 rats.
Vaccines 2 and 4 incorporated the T-cell epitope YSYFPSV from
tetanus toxin (TT593–599) as a component for generating CD4+ T-cell
help in the production of anti-METH/meth Abs [25]. To deter-
mine the involvement of this T-cell help, T-cells from spleens of
METH/meth-positive rats immunized with Vaccines 2 and 4 were
isolated and incubated with BSA modified with METH or a vehicle
control. Fig. 3 shows an increased stimulation index (6.8±0.87) for
Vaccine 2 and (3.5±1.1) for Vaccine 4 when METH-modified BSA
was used as the antigen relative to vehicle control (1.9±0.19), sup-
porting the involvement of T-cell help in the production of Abs to
meth. These data further indicate that Vaccine 2would serve as the
best candidate vaccine for use in self-administration studies.
To determine the ability of these anti-METH/meth Abs to reduce
meth distribution to the brain, rats were immunized with Vac-
cine 2 and thenmonitored for changes in meth self-administration
relative to sham-vaccinated controls. Fig. 4 shows the number of
infusions earned per session across each FR schedule. The ANOVA
on the infusions earned across the initial FR1 schedule indicated a
main effect of Group, F (1, 8) = 7.10, P=0.029; themain effect of Ses-
sionand theGroup× Session interactionwerenot significant, F’s < 1.
This analysis indicates that the Vaccine group tookmoremeth than
Fig. 3. T-cell proliferation assay from male Wistar rats immunized with a vehicle
control, Vaccine 2, and Vaccine 3. T-cells were isolated from the spleen, incubated
with a control orMETH-modifiedBSAmeth for 48h, andpulsedwith [3H]-thymidine
overnight. Data are expressed as a stimulation index of 3 rats. *P=0.002 significantly
different from the vehicle control.
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Fig. 4. Self-administration of meth following immunization with Vaccine 2. Data
are expressed as the mean number of meth infusions taken per session across each
fixed ratio (FR) schedule of reinforcement for rats in the Vaccine and Control groups.
the Control groupduring this initial phase of self-administration. As
meth self-administration progressed and the reinforcement sched-
ule increased, this difference was no longer detected: FR3 (F’s≤1.7,
p’s≥0.226), FR5 (F’s≤1.25, p’s≥0.308), FR10 (F’s < 1). Both groups
acquired the discrimination between the active and inactive lever
(data not shown). However, onset of the discrimination was faster
for the Vaccine group than the Control group. The Vaccine group
had significantly more than half of their subjects responding on
the active lever by Sessions 4 and 5 of the FR1, whereas the Con-
trol group did not meet the criterion until Sessions 3 and 4 of the
FR3. Breakpoints on the PR schedule were highly variable and did
not differ between the Vaccine (70±34.5) and Control (47±18.1)
group, t<1.
Following the meth self-administration studies, the animals
were checked for serum Ab titers to meth. As shown in Fig. 5 only
background levels of Ab to the meth was observed shortly after
self-administration (186±17). However, following a 34-day clear-
ance of meth, serum Ab titers rebounded to the previous levels
(1664±543) of Ab seen with the original immunizations of Vac-
cine 2. These data indicate that the anti-meth Abs were bound
by free, circulating meth during self-administration and, conse-
quently, were masked from our binding assays.
Fig. 5. Immune serum activity to METH-modified BSA 1 week after self-
administration of meth in male Wistar rats immunized with a vehicle control or
Vaccine 2. Data represent the mean± S.E. of 5–6 rats. *P≤0.001 as compared to the
vehicle control or the vaccinated rats after 1 day of meth self-administration.
4. Discussion
The results of this study indicate that immunization with a
peptide-based, molecular adjuvant (EP54)-containing vaccine to
meth (Vaccine 2) can generate meth-specific Abs in the sera of
rats capable of altering meth self-administration. In contrast to the
immunoconjugate vaccines to meth [16] and other addictive drugs
[8–14]madeby the covalent conjugation of numerous drughaptens
to a carrier protein admixed with adjuvant, it is noteworthy that
these anti-meth responseswere generated by a vaccine that carried
only oneMETH hapten and were produced by immunization in the
absence of added adjuvant – the vaccine dissolved merely in PBS.
Development of vaccines from other laboratories has demon-
stratedsimilarAb titers to theonedescribed in this article.However,
the majority of haptenated vaccines to nicotine, cocaine, and meth
wereall coupled toKLH (keyhole limpethemocyanin) or someother
large carrier protein and immunized with oil based adjuvants such
as Ribi or Freunds [14,16,30,31]. Such drug hapten–protein conju-
gate vaccines to nicotine and cocaine have been taken into phases
I and II trails with some success [12,32]. This present study and
our previous nicotine vaccine study [15] are the first to use a novel
peptide-based vaccine in the absence of large carrier proteins and
the use of added adjuvants. The principal experimental approach
for attenuating the effects of meth overdose/abuse is the use of
anti-meth monoclonal Abs (MAbs) that are first generated in mice
[33,34]. TheseMAbs are then infused into rats and then tested using
self-administration studies [35,36]. The EP54-containing vaccines
described in this study offer clear potential advantages over the
use MAbs and protein-conjugate vaccines in that active immuniza-
tion as often as is need is possible to invoke a sustained, protective
immune response to attenuate the psychoactive effects of meth
with little/no inflammatory side-effects from added adjuvants.
The immunologic results presented in this study are consistent
with those observed with an EP54-containing vaccine to nicotine
[15] and with a mechanism we proposed earlier to describe the
molecular adjuvant properties of EP54 (YSFKPMPLaR) and its abil-
ity to induce Ag-specific Ab and cell-mediated immune responses
[20–24]. Briefly, EP54 selectively interacts with C5aRs on anti-
gen presenting cells (especially DCs) and induces the release of
Th1 cytokines. The C5aR/ligand complex then internalizes, which
carries the covalently attachedAg/epitope into intracellular Ag pro-
cessing pathways. Here, the Ag/epitope is processed and associates
with HLA/MHC determinants for expression on the DC surface.
Thus, EP54 delivers both the Ag and stimulatory signals to C5aR-
bearing DCs.
Vaccine 2 was designed to exploit the assistance of a promiscu-
ous T-cell epitope (YSYFPSV) derived from tetanus toxin (TT593–599).
YSYFPSV is processed by DCs, presented in the context of MHC/HLA
class II, and invokes CD4+ T-cell help to B cells for the produc-
tion of Abs [25]. Thus, we reasoned that METH-YSYFPSV likewise
would be processed and presented by DCs, particularly when tar-
geted to and activated by EP54. Our expectation was that the
presented YSYFPSV moiety would induce the necessary CD4+ help
for the appropriate B cell(s) to recognize the attached METH hap-
ten, which together would drive the hapten-specific Ab response.
This involvement of the TT593–599 epitope appears substantiated
by the anti-METH/meth immune outcomes generated by Vaccines
2 and 4 and the relative lack of response with Vaccines 1 and 3,
which lacked this epitope. This epitope involvement in the anti-
meth immune outcome is further substantiated by the increased
stimulation index observed from T-cells obtained from the spleens
of rats immunized with Vaccine 2.
The use of TT593–599 in these EP54-containing vaccines is attrac-
tive because it is well-characterized immunologically, is small and
easy to synthesize, and has been used in other larger, peptide-
based vaccines to invoke CD4+ T-cell help for B cells to generate
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Ag-specific Abs [25]. Also, it is possible that this CD4+ response in
humans may be readily invoked with such TT/molecular adjuvant-
containing vaccines to meth since most people already have been
immunized to tetanus.
Given the ability of Vaccine 2 to induce meth-specific Abs in
serum, the efficacy of this immune outcome to reduce the psy-
choactive effects ofmethwasevaluated inmeth self-administration
in rats. There was a significant but transient effect of Vaccine
2 on meth self-administration. Surprisingly, vaccinated rats dis-
played an increase rather than a decrease in drug intake relative
to controls only in the initial FR1 phase of self-administration. This
pattern of results is consistent with the view that meth-specific
Abs are sequestering meth in peripheral circulation, thus decreas-
ing, at least early on, the ability of some of the meth from entering
the central nervous system; i.e., meth-specific Abs are essentially
functioning as a pharmacokinetic antagonist [13]. Vaccinated rats
presumably compensated for this pharmacokinetic antagonism by
increasing drug intake. Indeed, such compensation is seen in self-
administration experimentswhenpharmacological antagonists are
used [28,37,38].
Following the self-administration studies, animals were tested
for the presence of meth-specific Abs. These assays showed barely
discernable levels of Abs, which were lower than unimmunized
control animals. When these animals were allowed to recovery
from meth self-administration and the sera were re-tested, anti-
meth Ab levels returned to previous levels. This suggests that the
Abs bound free meth with high affinity/avidity in vivo, minimizing
meth access to the brain and the need for animals to compensate by
increasing self-administration. Thus, vaccinated animals behaved
essentially like controls in the later phases of self-administration.
It appeared that animals would take in more meth to compensate
for the effects of the vaccine; however, later when all the Abs were
saturated with meth, they were equal to the controls.
These data suggest that this vaccine could be useful in absorbing
some of the meth in peripheral circulation early in meth exposure.
However, our findings suggest that compensationmayoccur result-
ing in overall increased meth administration. This finding implies
that such a vaccination approach would be most effectively used
in association with standard behavior modification and the use
of other medications as a complementary approach to stop meth
use and addiction. Some authors have suggested that vaccination
couldbeusedasapreventionstrategy for at-risk individuals [13,38],
whereasothershaveexpressed someskepticismandurgedextreme
caution if such an approach is routinely adopted [26,39,40]. At least
with vaccination as a preventative againstmeth abuse, our findings
that vaccinated rats increase early meth intake suggests the latter
perspectivemay bemore appropriate. It will be of interest in future
research to determine if similar compensation occurs in an animal
model that simulates a relapse opportunity in a meth addict that
has been abstinent for some time (i.e., as an intervention approach).
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